FDA Prioritizes New Hepatitis C Drug
Johnson & Johnson announced priority review for its hepatitis C drug simeprevir. In this video, health-care analyst David Williamson discusses the positive aspects of this decision and how a competing drug also angling for approval may actually help boost sales for J&J.
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.Â
The article FDA Prioritizes New Hepatitis C Drug originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavid.The Motley Fool recommends Gilead Sciences. It recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.